New strategy for treating common retinal diseases shows promise A potential treatment based on a natural protein may offer broader benefits than existing drugs Scientists at Scripps Research have uncovered a potential new strategy for treating eye diseases that affect millions of people around the world, often resulting in blindness.
New insight on how people with retinal degenerative disease can maintain their night vision for a relatively long period of time has been published today in the open-access eLife journal. The study suggests that second-order neurons in the retina, which relay visual signals to the retinal ganglion cells that project into the brain, maintain their activity in response to photoreceptor degeneration to resist visual decline -- a process known as homeostatic plasticity.
When the eye isn't getting enough oxygen in the face of common conditions like premature birth or diabetes, it sets in motion a state of frenzied energy production that can ultimately result in blindness, and now scientists have identified new points where they may be able to calm the frenzy and instead enable recovery. In this high-energy environ, both the endothelial cells that will form new blood vessels in the retina -- which could improve oxygen levels -- and nearby microglia -- a type of macrophage that typically keeps watch over the retina -- prefer glycolysis as a means to turn glucose into their fuel.
February Is Age-Related Macular Degeneration (AMD) / Low-Vision Awareness Month What is Macular Degeneration? Age-Related Macular Degeneration (AMD) is a relatively common eye condition. It is the leading cause of vision loss in adults 55 and over. It affects more than 10 million Americans – more than both glaucoma and cataracts combined.
Copyright © 2019 all rights reserved.